Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma

Schlapbach, Christoph
Yerly, Daniel
Daubner, Barbara
Yawalkar, Nikhil
Hunger, Robert E

Open link

Publication date

January 2011

DOI

10.1016/j.jdermsci.2011.02.001

Publisher

Elsevier BV

ISSN

0923-1811

Citation count (estimate)

Abstract

There is currently no curative therapy for cutaneous T cell lymphoma (CTCL). New therapies are therefore needed. Telomerase, the enzyme that allows for unrestricted cell divisions of cancer cells, is a promising target for cancer therapy. The telomerase-specific peptide vaccination GV1001 has shown promising results in previous studies. Since telomerase is expressed in malignant cells of CTCL, GV1001 vaccination in CTCL is a promising new therapeutic approach